Overview

A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

Status:
Not yet recruiting

Trial end date:
2023-09-22

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to investigate the safety and tolerability of the study drug LY3457263 when administered alone or in combination with glucagon-like peptide 1 (GLP-1) receptor agonist (RA) in participants with type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to approximately 16 weeks excluding the screening period for each participant and include up to 17 visits.

Phase:

Phase 1

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Dulaglutide